Some COVID-19 patients still have coronavirus after symptoms disappeared, according to a new study. Researchers found that half of the patients they tested for mild COVID-19 infection still have coronavirus...

Evox and Takeda enter rare disease collaboration

Evox Therapeutics has signed a rare disease-focussed partnership with Takeda to develop up to five novel protein replacement and mRNA therapies. This will include Evox’s...

Exscientia to identify COVID-19 drugs with Diamond Light Source & Scripps Research

AI driven drug discovery company, Exscientia, has teamed up with Diamond Light Source – the UKs national synchrotron facility – a Scripps Research division...

Grifols collaborating with US gov to produce targeted COVID-19 treatment

Grifols, a Spanish producer of plasma-derived medicines, is formally collaborating with the US government to provide the first treatment specifically targeting Covid-19. The company has...

View the Online Magazine

- Advertisement -

Launches

Liquid formulation for treatment of sickle cell now available

The EMA licensed liquid-form of hydroxycarbamide developed by pharmaceutical manufacturer Nova Laboratories is now available to sickle cell disease specialists in the UK and...

Pain management programme leads to radical reduction in opioid prescriptions

A new pain management programme implemented by surgeons in large healthcare systems led to a 64% reduction in opioid prescriptions of five or more...

Novartis agrees lower price for canakinumab on NHS

NHS England has struck a deal with Novartis to fund a canakinumab, a life-changing fever, headache and painkilling drug for paediatric patients. Periodic fever syndromes...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Novartis donates 130m doses of malaria drug to support Covid-19 response

Novartis has committed to donate up to 130 million doses of generic anti-malaria drug hydroxychloroquine to support the global Covid-19 pandemic response. Hydroxychloroquine and a...

Mitigation may be better than quarantine against Covid-19, says GlobaData

Mitigation might be a better strategy than quarantine to combat the spread of Covid-19, says data and analytics company, GlobalData. As the coronavirus continues to...

Sandoz pledges to ‘keep prices stable’ for essential meds amid coronavirus supply fears

Sandoz, the generics division of Novartis, has pledged to keep the prices stable for a basket of essential medicines it markets amid growing global...

Dearth of new antibiotics threatens efforts to contain AMR, says WHO

Declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant infections, says the World Health...

Approvals

FDA okays trial to test Actermra in severe COVID-19 pneumonia

A clinical trial to evaluate the safety and efficacy of intravenous Actemra (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19...

FDA Emergency Authorisation for Roche’s cobas SARS-CoV-2 test

Roche’s cobas SARS-CoV-2 test to detect the novel coronavirus that causes Covid-19 has received Emergency Use Authorisation from the FDA. It is intended for the...

NICE recommends migraine drug Ajovy for use on NHS

Some 10,000 people in England could benefit from Teva Pharmaceuticals’ migraine drug, Ajovy (fremanezumab), says NICE in final draft guidance published this week. Fremanezumab costs...

Expanded indication for Opdivo plus Yervoy to treat HCC

Bristol-Myers Squibb’s immuno-oncology combination of Opdivo (nivolumab) and Yervoy (ipilimumab) is now approved to treat four types of cancer after it was approved by...

FDA approves Ofev for progressive interstitial lung diseases

Ofev, the first treatment for patients with chronic fibrosis interstitial lung diseases (ILD) with a progressive phenotype, has been approved in the US. The approved...

New treatment for Cushing’s disease gets green light

Isturisa (osilodrostat) oral tablets have been approved in the US for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have...

Manufacturiung

Finance

Funding could help Oz researchers cut timeline for effective Covid-19 vaccine

The University of Queensland could help cut the timeline for an effective Covid-19 vaccine by six months thanks to a $17 million funding injection. The...

Nurix to advance pipeline to clinical development after raising $120m

Nurix Therapeutics, a San Fran company developing targeted protein modulation drugs, will advance its pipeline into clinical development after closing an oversubscribed financing. The $120...

UK commits £12m for preventable diseases research

An extra £12 million has been committed by the UK Government to the National Institute for Health Research (NIHR) in 2020-21 to fund research...

Kymera raises funds to advance protein degrader pipeline, platform

Kymera Therapeutics, a Cambridge, Massachusetts-based biotech inventing breakthrough protein degrader medicines, has closed a $102 million Series C financing. The round was led by Biotechnology...

Research & Development
Latest

Coronavirus remains after COVID-19 symptoms clear in some patients – research

Some COVID-19 patients still have coronavirus after symptoms disappeared, according to a new study. Researchers found that half of the patients they tested for mild...

Evox and Takeda enter rare disease collaboration

Evox Therapeutics has signed a rare disease-focussed partnership with Takeda to develop up to five novel protein replacement and mRNA therapies. This will include Evox’s...

Exscientia to identify COVID-19 drugs with Diamond Light Source & Scripps Research

AI driven drug discovery company, Exscientia, has teamed up with Diamond Light Source – the UKs national synchrotron facility – a Scripps Research division...

Grifols collaborating with US gov to produce targeted COVID-19 treatment

Grifols, a Spanish producer of plasma-derived medicines, is formally collaborating with the US government to provide the first treatment specifically targeting Covid-19. The company has...

Sorrento & Mabpharm to develop, commercialise potential Covid-19 treatment

San Diego’s Sorrento Therapeutics has entered into an exclusive license agreement with China-based antibody biopharma, Mabpharm, for the clinical development and commercialisation of the...

Appointments

Jazz appoints industry veteran amid expansion

Jazz Pharmaceuticals has appointed industry veteran Samantha Pearce as its Senior Vice President of Europe/Rest of World. Before joining the the Dublin-headquartered biopharma, Ms Pearce...

Gilead poaches senior BMS player for research biology division

Gilead has poached a senior player from Bristol-Myers Squibb (BMS) to serve as the Senior Vice President of its Research Biology division. In his previous...

Illumina welcome former FDA commissioner Scott Gottlieb to board

Scott Gottlieb, the former commissioner of the US Food and Drug Administration (FDA), has joined Illumina’s Board of Directors. Gottlieb, who resigned from helming the...
- Advertisement -

Expanded indication for Opdivo plus Yervoy to treat HCC

Bristol-Myers Squibb’s immuno-oncology combination of Opdivo (nivolumab) and Yervoy (ipilimumab) is now approved to treat four types of cancer after it was approved by...

FDA approves Ofev for progressive interstitial lung diseases

Ofev, the first treatment for patients with chronic fibrosis interstitial lung diseases (ILD) with a progressive phenotype, has been approved in the US. The approved...